A5101993578- RNA modifications and cancer
- Ferroptosis and cancer prognosis
- Lipid metabolism and biosynthesis
- Ubiquitin and proteasome pathways
- Genetic factors in colorectal cancer
- Wnt/β-catenin signaling in development and cancer
- Diet, Metabolism, and Disease
- Cancer, Hypoxia, and Metabolism
- Cancer-related molecular mechanisms research
- Plant biochemistry and biosynthesis
- Cancer-related gene regulation
- Peroxisome Proliferator-Activated Receptors
- Cancer-related Molecular Pathways
- Adipose Tissue and Metabolism
- Lung Cancer Treatments and Mutations
- Epigenetics and DNA Methylation
- Cancer Mechanisms and Therapy
- Endoplasmic Reticulum Stress and Disease
- Biological Activity of Diterpenoids and Biflavonoids
Korea Research Institute of Bioscience and Biotechnology
2020-2023
Korea University of Science and Technology
2020-2023
Handok (South Korea)
2015
Mijin Park, Byul Moon, Jong-Hwan Kim, Seung-Jin Seon-Kyu Kihyun Jaehoon Seon-Young Jeong-Hoon and Jung-Ae Kim. Mol. Cells 2022;45:550-63. https://doi.org/10.14348/molcells.2022.0009
Abstract Background Anchoring filament protein ladinin-1 (LAD1) was related to the aggressive progression of breast, lung, laryngeal and thyroid cancers. However, association LAD1 with colorectal cancer remained unknown. Here, determine relationship progression, we explored effect loss on malignant features cells. Methods We constructed LAD1-depleted cell lines examined deficiency phenotypic molecular cells in vitro. The function metastasis vivo by establishing a spleen-to-liver mouse model....
Abstract Von Hippel–Lindau (VHL) is a tumor suppressor that functions as the substrate recognition subunit of CRL2VHL E3 complex. While substrates VHL have been identified, its suppressive role remains to be fully understood. For further determination substrates, we analyzed physical interactome and identified histone H3K9 methyltransferase SETBD1 novel target. SETDB1 undergoes oxygen-dependent hydroxylation by prolyl hydroxylase domain proteins complex recognizes hydroxylated for...
Other SectionsABSTRACTINTRODUCTIONRESULTSDISCUSSIONMATERIALS AND METHODSACKNOWLEDGEMENTSCONFLICTS OF INTERESTFIGURESREFERENCES
We identified azabicyclo[3.1.0]hexane derivatives that are active diacylglycerol acyltransferase‐1 ( DGAT )‐1 inhibitor. Among the series, compound 6b showed good in vitro activity toward human ‐1, selectivity ‐2, and liver microsomal stability. Compound exhibited no CYP inhibition, hERG binding, or cell cytotoxicity. Additionally, reduced level of plasma triglyceride after oral administration mice.